Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

GSK to Invest £200 Million in UK Manufacturing

Published: Thursday, December 12, 2013
Last Updated: Thursday, December 12, 2013
Bookmark and Share
The series of investments will support the delivery of the company’s pipeline of new medicines and create a centre for pharmaceutical manufacturing innovation in the UK.

Manufacturing sites in Ware, Hertfordshire and Worthing, Sussex will be upgraded with new state-of-the-art equipment. In addition GSK will establish a new facility dedicated to harnessing innovative technologies with the potential to transform both the way medicines are made and the company’s supply chain.

Roger Connor, GSK’s President of Global Manufacturing and Supply, said: “The establishment of the Patent Box has transformed how we see the UK as a place to invest. As a result, last year we announced we were building our first new factory in the UK for 40 years. The investments announced today are in addition to that and will allow us to harness new technologies that have the potential to deliver a step-change in how we make medicines. These new technologies could significantly reduce costs, improve quality and enable the manufacture of medicines in weeks rather than years and I am delighted that we have been able to bring these investments to the UK.”

Jeremy Hunt, Health Secretary, said: "On the day when we are bringing together the health leaders of the developed world, researchers and pharmaceutical countries to launch the global fight against dementia, it is great to see GSK investing more money and resources into UK life sciences. GSK's decision to invest in the UK shows we are creating the right conditions for global investment, leading to job creation and growth, as well as maintaining the UK's place as a world leader in innovation."

The investments announced today comprise:

  • New manufacturing facilities in Ware for the RelvarTM ElliptaTM inhaler – the latest generation of GSK’s inhaler devices for respiratory disease. The Ellipta device was developed at Ware and will now be produced at the site before being exported worldwide.

  • In Worthing, a new bulk sterile building and filling line will be built for the company’s leading antibiotic medicine AugmentinTM, which is exported to 150 countries.

  • A new centre for manufacturing innovation will be built, dedicated to transforming emerging science and technologies into practical manufacturing applications. These technologies range from mimicking nature using enzymes and biologically inspired catalysts, to using nano-technologies to create intelligent drug product formulations which minimise side-effects and enhance efficacy. Although subject to further decisions, GSK’s preferred site for the location of the new centre is Ware, Hertfordshire where the company already has manufacturing and R&D facilities in one location.

The establishment of the Patent Box has made the UK a globally competitive location for investment in high-tech manufacturing and research facilities. Today’s investment is on top of the £500 million GSK announced in March last year which included a commitment to build a new factory in Ulverston, Cumbria. That investment is creating up to 1,000 jobs and continues to progress on schedule. GSK also recently announced an investment of £25 million to expand its operations in Montrose to support the delivery of its new pipeline of medicines.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK Receives Positive CHMP Opinion in Europe for Asthma Therapeutic
GlaxoSmithKline has announced that the CHMP of the EMA has issued a positive opinion recommending marketing authorisation for mepolizumab, which will be commercialised under the brand name Nucala, as an add-on treatment for severe refractory eosinophilic asthma in adult patients.
Monday, September 28, 2015
GSK and the Bill & Melinda Gates Foundation to Accelerate Research into Vaccines
The joint initiative will endeavour to make vaccines more resistant to heat, thus reducing the need for refrigeration.
Wednesday, October 30, 2013
Malaria Vaccine Could be Available from 2015
GSK candidate reduces disease over 18 Months of follow-up in late-stage study of more than 15,000 infants and young children.
Tuesday, October 08, 2013
GSK Gives Update on Plans to Share Detailed Clinical Trial Data
New online system will enable researchers to request access to patient level data from GSK clinical trials to help further scientific understanding and improve patient care.
Wednesday, May 08, 2013
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma
GSK intends to commence global regulatory filings in COPD and asthma from mid-2012.
Monday, January 09, 2012
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos